MPH Health Care AG (93M1) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of MPH Health Care AG stock €57.60, price €28.70, upside +100.7%, quality 74 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range €6.86 – €29.20 · fair‑value band €25.85 – €90.03 · the €28.70 price screens below the €57.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow MPH Health Care in your weekly email
Every Wednesday you see whether MPH Health Care is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It operates through Beauty, Pharma, and Real Estate segments.
Show moreShow less
The company offers medical-aesthetic beauty surgeries and treatments, as well as operation and provision of medical infrastructures for partner companies; and sells pharmaceuticals and medical products in the areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine.
It also provides plastic and aesthetic treatments and surgeries; operates European mail-order pharmacy.
In addition, the company is involved in real estate business; acts as an investment manager; renewable energies; and project development, including new residential construction/owner occupied homes.
The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was incorporated in 2008 and is based in Berlin, Germany.
Stock analysis
MPH Health Care AG (93M1) currently trades at €28.70, while our model-based Fair Value estimate is €57.60, implying the stock looks roughly 50% undervalued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of €157.48 per share, and 8 of the 12 models we run sit above the €28.70 price.
Bear case: the Dividend Discount group reads lowest at €13.45, and 4 of the 12 models stay below the price. Data coverage for this calculation is high.
Scenario range: €25.85 (bear) to €90.03 (bull), the price of €28.70 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
MPH Health Care AG reported revenue of €364M in FY2025 versus €4.4M in FY2021, a compound +202.3%/yr. Reported net income was €29.3M in FY2025.
Key figures
Market cap €123M Micro · P/E ratio 2.5 · P/S ratio 2.43 · EPS (TTM) €11.31 · Net margin 95.6% · Return on equity 21.4% · Return on assets (EBIT) 8.8% (5-year average) · Operating margin 100%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 82 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −16% fair-value upside, at 101%, 93M1 screens cheaper than that median.
Fair Value models
Bear€25.85Fair Value €57.60Bull€90.03
Price €28.70 · Upside +100.7%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€5.39 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +21.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +21.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 21.5% / −9.6%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.183% → 10%
⚠ Revenue per share shrinking 29.6%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 2.59 per share, median 13.7 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 588 stocks
Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+100.7% · Top 25%
Profitability
Return on equity (12 months)21.4% · Top 25%
Return on assets11.4% · Top 25%
Net margin (12 months)95.6% · Top 25%
Operating margin (12 months)100.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)9.5% · Above median
Dividend yield (12 months)17.4% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Asset Management median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MPH Health Care AG Fair Value". https://www.fairvalue-calculator.com/stock/93M1
Frequently asked questions
Is MPH Health Care AG (93M1) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €57.60 versus a price of €28.70, about +101% upside (undervalued).
What is the fair value of 93M1?
Our model-based fair value for MPH Health Care AG is €57.60 (as of Nov 6, 2026), built from audited fundamentals. The current price: €28.70.
What is the quality score of 93M1?
MPH Health Care AG has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MPH Health Care AG (93M1)?
Our model-based price target is the fair value of €57.60 (as of Nov 6, 2026) from 12 valuation models. Cautious scenario €25.85, optimistic scenario €90.03. It is a calculation from audited fundamentals, not an analyst target.
What is the MPH Health Care AG stock forecast for 2026?
Our models put fair value at €57.60, about +101% upside versus a price of €28.70 (undervalued). Cautious scenario €25.85, optimistic scenario €90.03. The calculation is refreshed regularly with new filings.
What growth is priced into MPH Health Care AG (93M1)?
For today's price to be fair in a discounted-cash-flow model, MPH Health Care AG would have to grow free cash flow by more than 80 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 6 years revenue grew +96.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 93M1 use?
Our models discount MPH Health Care AG at 12.6 %: a base by market capitalisation (micro), damped by beta 1.05, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MPH Health Care AG that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has MPH Health Care AG (93M1) delivered so far?
Over the past 6 years revenue at MPH Health Care AG grew +96.6 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MPH Health Care AG (93M1) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into MPH Health Care AG (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MPH Health Care AG (93M1)?
The free-cash-flow yield on the price is 0.10 %: that much free cash flow MPH Health Care AG produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MPH Health Care AG (93M1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MPH Health Care AG it is €57.60 per share (as of Nov 6, 2026), against a price of €28.70. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is MPH Health Care AG stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 93M1 trades below its calculated fair value: price €28.70, fair value €57.60, a gap of about +101% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 93M1?
No. The price is what the market pays today (€28.70); the fair value is what the company's own numbers justify (€57.60). For MPH Health Care AG the two are €28.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is MPH Health Care AG worth?
The market values MPH Health Care AG at about €123M (market capitalisation, as of Nov 6, 2026). Per share that is €28.70; our models calculate a fair value of €57.60 per share.
What do the bullish and bearish scenarios say about 93M1?
Our models span a range for MPH Health Care AG: cautious scenario €25.85, base €57.60, optimistic €90.03 per share (as of Nov 6, 2026, price €28.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 93M1?
MPH Health Care AG trades at a price-to-earnings ratio of 2.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €57.60 is built from several models across several years. Other multiples: P/B 0.5, P/S 2.4, EV/EBITDA 2.5.
How solid is the balance sheet of MPH Health Care AG (93M1)?
Balance-sheet figures for MPH Health Care AG (as of Nov 6, 2026): return on equity 21.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 93M1 from its 52-week high?
MPH Health Care AG trades at €28.70, about 2% below its 52-week high of €29.20 and 98% above the low of €14.46 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €57.60 is for.
Which stocks are comparable to MPH Health Care AG?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Asset Management Ltd, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MPH Health Care AG stock attractive at the current price?
The data as of Nov 6, 2026: price €28.70, calculated fair value €57.60 (+101%), Quality Score 74/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 93M1 calculated?
We run MPH Health Care AG through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of €57.60 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. MPH Health Care AG currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MPH Health Care AG (93M1)?
The closing price on Nov 6, 2026 was €28.70. Our model-based fair value is €57.60, about +101% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MPH Health Care AG right now?
The model range is unusually wide (€25.85 to €90.03). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Where does the earnings growth of MPH Health Care AG (93M1) come from?
Earnings per share at MPH Health Care AG grew −6.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −3.0 %, EBIT margin +21.5 %, tax rate −0.3 %, residual (interest, one-offs) −20.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of MPH Health Care AG
How large is the market capitalisation of MPH Health Care AG (93M1)?
The market capitalisation of MPH Health Care AG is €123M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MPH Health Care AG (93M1)?
The price-to-sales ratio of MPH Health Care AG is 2.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MPH Health Care AG (93M1)?
Earnings per share at MPH Health Care AG are €11.31 (price ÷ EPS = P/E 2.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MPH Health Care AG (93M1)?
The net margin of MPH Health Care AG is 95.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MPH Health Care AG (93M1)?
The return on equity (ROE) of MPH Health Care AG is 21.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MPH Health Care AG (93M1)?
On an EBIT basis the return on assets of MPH Health Care AG is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MPH Health Care AG (93M1)?
The operating margin of MPH Health Care AG is 100% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MPH Health Care AG (93M1)?
Revenue at MPH Health Care AG is growing +9.5% versus a year earlier (3y avg +276%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MPH Health Care AG (93M1)?
Earnings per share at MPH Health Care AG are growing −31.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does MPH Health Care AG (93M1) carry?
The net debt of MPH Health Care AG is €10.6M (fiscal year 2025, ≈ 86.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch MPH Health Care AG in the live analysis
One click puts MPH Health Care AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026